NCT04429373

Brief Summary

Implant retained overdentures are a cost-effective treatment for elderly patients suffering from complete tooth loss. Despite the high success rate of implants in the general population, older adults lacking all teeth are a challenging population for implant therapy, often presenting limited bone disponibility, narrow alveolar ridges, diminished bone density, scarce inserted gingiva and several co-morbidities.Thus, improving their possibility of success in implant therapy avoiding further surgical interventions is key. Platelet-rich fibrin (PRF) is a blood derivate that can be easily and economically obtained from patients and that has shown promise of reducing the complications and improving the success of implant therapy, nevertheless its benefits in patients receiving implant retained overdentures has not been stablished. It is possible that PRF can improve the results and diminish the complications of implant therapy in older adults. The investigation aims to demonstrate that the use of platelet-rich fibirn (PRF) is safe and beneficial for implant treatment in older adults suffering from complete tooth loss.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 9, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 12, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

November 30, 2020

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2022

Completed
Last Updated

April 22, 2021

Status Verified

April 1, 2021

Enrollment Period

1.7 years

First QC Date

June 9, 2020

Last Update Submit

April 20, 2021

Conditions

Keywords

dental implantsplatelet-rich plasmedentulous jaw

Outcome Measures

Primary Outcomes (1)

  • Implant stability

    primary implant stability of mandibular implants in edentulous patients using resonance frequency analysis (RFA).

    6 months

Secondary Outcomes (2)

  • Keratinized tissue thickness around implant neck

    6 months

  • Keratinized tissue width around implant neck

    6 months

Study Arms (2)

Implant installation with PRF

EXPERIMENTAL

PRF membrane over the buccal aspect of implant site

Procedure: Implant installation with PRF membrane

Implant installation without PRF

ACTIVE COMPARATOR

Implant installation contralateral to the the experimental implant, without PRF membrane

Procedure: Implant installation without PRF membrane

Interventions

Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation

Implant installation with PRF

Implant installation contralateral to the experimental side without PRF membrane

Implant installation without PRF

Eligibility Criteria

Age60 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • mandibular edentulous
  • \> 60 years old

You may not qualify if:

  • physical or psychological impediment for dental surgery
  • dental extraction \< 6 months in the mandible
  • anticoagulant treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

San Camilo Hospital

San Felipe, Aconcagua, 969696, Chile

RECRUITING

MeSH Terms

Conditions

Jaw, Edentulous

Condition Hierarchy (Ancestors)

Jaw DiseasesMusculoskeletal DiseasesStomatognathic DiseasesMouth, EdentulousMouth DiseasesTooth Diseases

Central Study Contacts

Franco Cavalla, DDS PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Allocation sequence will be masked from participant, outcome assessor and statistician
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: We will conduct a split-mouth design randomized clinical trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 9, 2020

First Posted

June 12, 2020

Study Start

November 30, 2020

Primary Completion

July 31, 2022

Study Completion

December 20, 2022

Last Updated

April 22, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations